Cencora Inc. (COR)vsSanofi ADR (SNY)
COR
Cencora Inc.
$325.08
-0.67%
HEALTHCARE · Cap: $63.59B
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 597% more annual revenue ($325.78B vs $46.72B). SNY leads profitability with a 16.7% profit margin vs 0.5%. COR appears more attractively valued with a PEG of 0.78. COR earns a higher WallStSmart Score of 62/100 (C+).
COR
Buy62
out of 100
Grade: C+
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.9%
Fair Value
$254.20
Current Price
$325.08
$70.88 premium
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 134 in profit
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.5% margin — thin
Operating margin of 1.2%
Trading at 33.1x book value
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bear Case : COR
The primary concerns for COR are P/E Ratio, Profit Margin, Operating Margin. Thin 0.5% margins leave little buffer for downturns.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
COR profiles as a value stock while SNY is a mature play — different risk/reward profiles.
COR carries more volatility with a beta of 0.65 — expect wider price swings.
SNY is growing revenue faster at 6.9% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
COR scores higher overall (62/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?